{"id":66591,"date":"2026-05-28T21:20:25","date_gmt":"2026-05-28T13:20:25","guid":{"rendered":"https:\/\/flcube.com\/?p=66591"},"modified":"2026-05-28T21:20:26","modified_gmt":"2026-05-28T13:20:26","slug":"shanghai-yizhong-pharmas-trifunctional-antibody-fusion-protein-yxc-001-receives-ind-acceptance-in-china-novel-approach-targets-advanced-solid-tumors-with-precision-il-2-delivery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66591","title":{"rendered":"Shanghai Yizhong Pharma&#8217;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Yizhong Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688091:SHA\">SHA: 688091<\/a>) announced that China&#8217;s National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for <strong>YXC-001<\/strong>, a trifunctional antibody fusion protein targeting <strong>advanced solid tumors<\/strong>. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.<\/p>\n\n\n\n<h2 id=\"h-development-milestone\" class=\"wp-block-heading\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>YXC-001 \u2013 trifunctional antibody fusion protein<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>IND accepted for review by Chinese regulatory authority<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Advanced solid tumors<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical to Phase I transition<\/td><\/tr><tr><td><strong>Key Innovation<\/strong><\/td><td>Allosteric modification and targeted delivery of IL-2 within tumor microenvironment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-molecular-architecture-amp-mechanism\" class=\"wp-block-heading\">Molecular Architecture &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trifunctional Design:<\/strong> Integrates three therapeutic components:<\/li>\n\n\n\n<li><strong>PD-1 inhibitor:<\/strong> Pembrolizumab (immune checkpoint blockade)<\/li>\n\n\n\n<li><strong>Anti-VEGF antibody:<\/strong> Bevacizumab (anti-angiogenesis)<\/li>\n\n\n\n<li><strong>Optimized IL-2 analog:<\/strong> Aldesleukin with reduced toxicity profile<\/li>\n\n\n\n<li><strong>IL-2 Innovation:<\/strong> Spatial conformational redesign enables dual functionality:<\/li>\n\n\n\n<li><strong>Detoxification:<\/strong> Reduced systemic toxicity through allosteric modification<\/li>\n\n\n\n<li><strong>In situ activation:<\/strong> Enhanced efficacy through tumor microenvironment-specific activation<\/li>\n\n\n\n<li><strong>Therapeutic Strategy:<\/strong> Achieves &#8220;high local concentration with potent action&#8221; paradigm<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Minimizes off-target risks while maximizing effector cell activation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-rationale-amp-competitive-differentiation\" class=\"wp-block-heading\">Clinical Rationale &amp; Competitive Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Challenge in Current Therapy<\/th><th>YXC-001 Solution<\/th><\/tr><\/thead><tbody><tr><td><strong>Limited efficacy of monotherapies<\/strong><\/td><td>Triple-mechanism approach addresses multiple tumor escape pathways simultaneously<\/td><\/tr><tr><td><strong>Systemic toxicity of IL-2 therapy<\/strong><\/td><td>Conformational redesign reduces off-target effects while maintaining potency<\/td><\/tr><tr><td><strong>Poor tumor penetration<\/strong><\/td><td>Antibody scaffold enables targeted delivery to tumor microenvironment<\/td><\/tr><tr><td><strong>Resistance development<\/strong><\/td><td>Multi-pronged attack reduces likelihood of therapeutic resistance<\/td><\/tr><tr><td><strong>Suboptimal immune activation<\/strong><\/td><td>Localized high-concentration IL-2 maximizes effector cell recruitment and activation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The trifunctional approach represents a sophisticated evolution beyond combination therapies, as all three mechanisms are delivered as a single molecular entity with coordinated pharmacokinetics and targeted biodistribution.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-positioning\" class=\"wp-block-heading\">Market Impact &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Advanced Solid Tumors Landscape:<\/strong> High unmet need across multiple cancer types including lung, colorectal, and pancreatic cancers<\/li>\n\n\n\n<li><strong>Immuno-Oncology Evolution:<\/strong> Next-generation approach building on established PD-1 and VEGF inhibition with enhanced cytokine delivery<\/li>\n\n\n\n<li><strong>China Innovation Leadership:<\/strong> Demonstrates domestic biopharmaceutical capability in complex biologic engineering<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Novel mechanism could address limitations observed with current immunotherapies worldwide<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> IND acceptance positions Yizhong for potential first-in-human studies in 2026<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-development-pathway\" class=\"wp-block-heading\">Forward Development Pathway<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase I Focus:<\/strong> Safety, tolerability, and preliminary efficacy in advanced solid tumor patients<\/li>\n\n\n\n<li><strong>Biomarker Strategy:<\/strong> Likely to include PD-L1 expression, VEGF levels, and immune cell infiltration markers<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Future studies may explore synergies with other targeted therapies or standard-of-care regimens<\/li>\n\n\n\n<li><strong>Manufacturing Complexity:<\/strong> Single-molecule trifunctional design may offer advantages over combination product logistics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Shanghai Yizhong Pharmaceutical&#8217;s YXC-001 development program, including regulatory timelines and clinical development plans. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, manufacturing challenges, and competitive developments in the advanced solid tumors therapeutic area.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688091_20260528_Q2MD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688091_20260528_Q2MD.\"><\/object><a id=\"wp-block-file--media-20f4e04a-572f-4ab3-8030-e1b05c63b22c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688091_20260528_Q2MD.pdf\">688091_20260528_Q2MD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688091_20260528_Q2MD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-20f4e04a-572f-4ab3-8030-e1b05c63b22c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,90,18,25,2783,2782],"class_list":["post-66591","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-filings","tag-pd-1-l1","tag-potential-first-in-class","tag-sha-688091","tag-yizhong-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Yizhong Pharma&#039;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China&#039;s National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for YXC-001, a trifunctional antibody fusion protein targeting advanced solid tumors. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66591\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Yizhong Pharma&#039;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery\" \/>\n<meta property=\"og:description\" content=\"Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China&#039;s National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for YXC-001, a trifunctional antibody fusion protein targeting advanced solid tumors. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66591\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T13:20:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-28T13:20:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66591#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66591\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Yizhong Pharma&#8217;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery\",\"datePublished\":\"2026-05-28T13:20:25+00:00\",\"dateModified\":\"2026-05-28T13:20:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66591\"},\"wordCount\":481,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Clinical trial filings\",\"PD-1\\\/L1\",\"Potential first-in-class\",\"SHA: 688091\",\"Yizhong Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66591#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66591\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66591\",\"name\":\"Shanghai Yizhong Pharma's Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-28T13:20:25+00:00\",\"dateModified\":\"2026-05-28T13:20:26+00:00\",\"description\":\"Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China's National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for YXC-001, a trifunctional antibody fusion protein targeting advanced solid tumors. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66591#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66591\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66591#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Yizhong Pharma&#8217;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Yizhong Pharma's Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China's National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for YXC-001, a trifunctional antibody fusion protein targeting advanced solid tumors. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66591","og_locale":"en_US","og_type":"article","og_title":"Shanghai Yizhong Pharma's Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery","og_description":"Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China's National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for YXC-001, a trifunctional antibody fusion protein targeting advanced solid tumors. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.","og_url":"https:\/\/flcube.com\/?p=66591","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-28T13:20:25+00:00","article_modified_time":"2026-05-28T13:20:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66591#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66591"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Yizhong Pharma&#8217;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery","datePublished":"2026-05-28T13:20:25+00:00","dateModified":"2026-05-28T13:20:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66591"},"wordCount":481,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Clinical trial filings","PD-1\/L1","Potential first-in-class","SHA: 688091","Yizhong Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66591#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66591","url":"https:\/\/flcube.com\/?p=66591","name":"Shanghai Yizhong Pharma's Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-28T13:20:25+00:00","dateModified":"2026-05-28T13:20:26+00:00","description":"Shanghai Yizhong Pharmaceutical Co., Ltd. (SHA: 688091) announced that China's National Medical Products Administration (NMPA) has accepted for review its Investigational New Drug (IND) application for YXC-001, a trifunctional antibody fusion protein targeting advanced solid tumors. The novel therapeutic candidate represents a significant advancement in immuno-oncology through its innovative integration of three established modalities with enhanced precision delivery.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66591#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66591"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66591#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Yizhong Pharma&#8217;s Trifunctional Antibody Fusion Protein YXC-001 Receives IND Acceptance in China \u2013 Novel Approach Targets Advanced Solid Tumors with Precision IL-2 Delivery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66591"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66591\/revisions"}],"predecessor-version":[{"id":66593,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66591\/revisions\/66593"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}